Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1

Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1

Abstract Background Immunotherapy is currently under investigation in B3 Thymoma (TB3) and Thymic Carcinoma (TC). PD-L1 expression has been evaluated on a limited number of patients with selected antibodies. We aimed to analyze cohort of TB3 and TC with a panel of antibodies to assess the prevalence...

Full description

Bibliographic Details
Main Authors: Isabelle Rouquette, Estelle Taranchon-Clermont, Julia Gilhodes, Maria-Virginia Bluthgen, Romain Perallon, Lara Chalabreysse, Anne De Muret, Veronique Hofman, Alexander Marx, Marie Parrens, Veronique Secq, Vincent Thomas de Montpreville, Françoise Galateau-Salle, Pierre Brousset, Julie Milia, Nicolas Girard, Benjamin Besse, Thierry Jo Molina, Julien Mazières
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Biomarker Research
Subjects:
PD-L1
Immunotherapy
Thymic carcinoma
B3 thymoma
Online Access:https://doi.org/10.1186/s40364-019-0177-8

Internet

https://doi.org/10.1186/s40364-019-0177-8

Similar Items